Japan's Astellas Pharma is investigating the death of a 76-year-old patient in a trial of YM 311, an experimental anemia drug. The patient was taking 10 different medications besides YM 311, but a doctor has indicated that the death may be linked to the experimental drug. Astellas is in discussions with the FDA. Release (.pdf)